Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00870727 · ClinicalTrials.gov registry record · Phase 3
Study of Aripiprazole in the Treatment of Pervasive Developmental Disorders
A Phase 3 study of Pervasive Developmental Disorder, sponsored by Indiana University.
- Completed
- Registry status
- Phase 3
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT00870727 is a Phase 3 study of Pervasive Developmental Disorder that has completed, run by Indiana University. The registered enrollment target is 33 participants, below the 76-participant average among 7 other Pervasive Developmental Disorder trials with a reported enrollment target (57% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00870727, a Phase 3 study of Pervasive Developmental Disorder, has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to develop a better tolerated and more effective pharmacologic treatment with individuals with Pervasive Developmental Disorder. This is a double-blind, placebo-controlled study of aripiprazole in the management of the maladaptive behaviors of Pervasive Developmental Disorder. The investigators hypothesize that aripiprazole will be more effective than placebo for reducing aggression, tantrum and self-injurious behavior in children with Pervasive Developmental Disorder.
Conditions Studied
Interventions
- DRUG Placebo oral capsule
- DRUG Aripiprazole oral product
Study Locations (1)
Indiana
- Riley Hospital for Children, Christian Sarkine Autism Treatment Center - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2009-02 |
| Est. Completion | 2015-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00870727
The ClinicalTrials.gov registry entry for NCT00870727 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 76-participant average among 7 other Pervasive Developmental Disorder trials with a reported enrollment target (57% lower). The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pervasive Developmental Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo oral capsule is the first listed.
NCT00870727 reports 1 study location spanning 1 distinct geographic area - top geographies include Indiana.
Frequently Asked Questions
What is clinical trial NCT00870727 about?
NCT00870727 is a clinical study titled "Study of Aripiprazole in the Treatment of Pervasive Developmental Disorders". The purpose of this study is to develop a better tolerated and more effective pharmacologic treatment with individuals with Pervasive Developmental Disorder. This is a double-blind, placebo-controlled study of aripiprazole in the management of the maladaptive behaviors of Pervasive Developmental Dis...
What is the current status of trial NCT00870727?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 33 participants. The study started on 2009-02. Estimated completion is 2015-05.
What conditions does trial NCT00870727 study?
This clinical trial studies the following conditions: Pervasive Developmental Disorder.
What interventions are being tested in trial NCT00870727?
The interventions under investigation include: Placebo oral capsule (DRUG), Aripiprazole oral product (DRUG).
Who is sponsoring clinical trial NCT00870727?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00870727 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pervasive Developmental Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Impact of a Virtual Magic Trick Training Program
RECRUITING · Phase 2
-
Genetic Contributions to Autism Spectrum Disorders
ACTIVE NOT RECRUITING
-
Behavior Therapy for Irritability in Autism
ACTIVE NOT RECRUITING · NA
-
Confirmatory Efficacy Trial of Cognitive Enhancement Therapy for Adult Autism Spectrum Disorder
COMPLETED · NA
-
Services to Enhance Social Functioning in Adults With Autism Spectrum Disorders
COMPLETED · NA
-
GroundsKeeper: A Qualitative Study of Applied Game-based Interactives in Special Education Programs
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.